The guidelines are focused on primary prevention in adults to reduce the risk of atherosclerotic cardiovascular disease (ASCVD), i.e. acute coronary syndromes, myocardial infarction, stable or unstable angina, arterial revascularisation, stroke/transient ischaemic attack, peripheral arterial disease, as well as heart failure and atrial fibrillation. The basis for these new guidelines consists of the most important studies and guidelines for ASCVD outcomes on 9 topics described below per chapter. Table 1 shows the 10 ‘take-home messages’ that summarise the new guidelines [1].
Table 1: The guideline’s take-home messages for the primary prevention of cardiovascular disease
AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; HF, heart failure.
Posted on
Previous Article
« Barentsz Trial – Bi-parametric MRI versus multi-parametric MRI Next Article
Smartwatch can detect atrial fibrillation with high degree of accuracy »
« Barentsz Trial – Bi-parametric MRI versus multi-parametric MRI Next Article
Smartwatch can detect atrial fibrillation with high degree of accuracy »
Table of Contents: ACC 2019
Featured articles
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Substantial impact of temporary interruptions of warfarin versus DOAC
Smartwatch can detect atrial fibrillation with high degree of accuracy
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
High 5-year survival rates for older HF patients without initial severe comorbidity
Pulmonary Arterial Hypertension and Venous Thromboembolism
Interventional Cardiology
Vascular Medicine
Lower rates stroke/SE with DOACs in frail non-valvular AF patients
Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry
Convincing evidence of the role of icosapent in reducing subsequent CV events
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com